Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms

Cancer Letters

Volumn 295, Issue 1, 2010, Pages 7-16

  Wu, William Ka Kei ^a   Yiu Sung, Joseph Jao ^a   Lee, Chung Wa ^a   Yu, Jun ^a   Cho, Chi Hin ^a,b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colon cancer; Cyclooxygenase 2; Gastric cancer; Gene expression; Signaling

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MELOXICAM; MICRORNA; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ONO AE 2 227; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SULINDAC; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; COLON CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; INTESTINE POLYP; KIDNEY DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SMOKING; STOMACH CANCER; SURVIVAL RATE; TONGUE CANCER; TRANSACTIVATION; TUMOR REGRESSION; TUMOR VASCULARIZATION; UPREGULATION;

EID: 77953611147     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.03.015     Document Type: Review

References (112)

1. Abnet C.C., Freedman N.D., Kamangar F., Leitzmann M.F., Hollenbeck A.R., Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br. J. Cancer 2009, 100:551-557.
2. Chan A.T., Ogino S., Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356:2131-2142.
3. Takkouche B., Regueira-Méndez C., Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J. Natl. Cancer Inst. 2008, 100:1439-1447.
4. Jacobs E.J., Rodriguez C., Mondul A.M., Connell C.J., Henley S.J., Calle E.E., Thun M.J. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl. Cancer Inst. 2005, 97:975-980.
5. Slatore C.G., Au D.H., Littman A.J., Satia J.A., White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1203-1207.
6. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H.J., Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10:501-507.
7. Spagnesi M.T., Tonelli F., Dolara P., Caderni G., Valanzano R., Anastasi A., Bianchini F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994, 106:362-366.
8. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993, 328:1313-1316.
9. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
10. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Gordon G.B., Hawk E.T. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355:873-884.
11. Arber N., Eagle C.J., Spicak J., Rácz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355:885-895.
12. Jr Peek R.M. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother. Pharmacol. 2004, 54(Suppl. 1):S50-S56.
13. Burn J., Bishop D.T., Mecklin J.P., Macrae F., Möslein G., Olschwang S., Bisgaard M.L., Ramesar R., Eccles D., Maher E.R., Bertario L., Jarvinen H.J., Lindblom A., Evans D.G., Lubinski J., Morrison P.J., Ho J.W., Vasen H.F., Side L., Thomas H.J., Scott R.J., Dunlop M., Barker G., Elliott F., Jass J.R., Fodde R., Lynch H.T., Mathers J.C. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med. 2008, 359:2567-2578.
14. Giardiello F.M., Spannhake E.W., DuBois R.N., Hylind L.M., Robinson C.R., Hubbard W.C., Hamilton S.R., Yang V.W. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig. Dis. Sci. 1998, 43:311-316.
15. Grösch S., Tegeder I., Niederberger E., Bräutigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15:2742-2744.
16. Maier T.J., Janssen A., Schmidt R., Geisslinger G., Grösch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J. 2005, 19:1353-1355.
17. Wong B.C., Jiang X.H., Lin M.C., Tu S.P., Cui J.T., Jiang S.H., Wong W.M., Yuen M.F., Lam S.K., Kung H.F. Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Gastroenterology 2004, 126:136-147.
18. Grösch S., Tegeder I., Schilling K., Maier T.J., Niederberger E., Geisslinger G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J. 2003, 17:1316-1318.
19. Wakimoto N., Wolf I., Yin D., O'Kelly J., Akagi T., Abramovitz L., Black K.L., Tai H.H., Koeffler H.P. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res. 2008, 68:6978-6986.
20. Dolara P., Caderni G., Tonelli F. Nimesulide, a selective anti-inflammatory cyclooxygenase-2 inhibitor, does not affect polyp number and mucosal proliferation in familial adenomatous polyposis. Scand. J. Gastroenterol. 1999, 34:1168.
21. Akasu T., Yokoyama T., Sugihara K., Fujita S., Moriya Y., Kakizoe T. Peroral sustained-release indomethacin treatment for rectal adenomas in familial adenomatous polyposis: a pilot study. Hepatogastroenterology 2002, 49:1259-1261.
22. Peskar B.M. Role of cyclooxygenase isoforms in gastric mucosal defence. J. Physiol. Paris 2001, 95:3-9.
23. Brown J.R., DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 2005, 23:2840-2855.
24. Wang D., Dubois R.N. Prostaglandins and cancer. Gut 2006, 55:115-122.
25. Sakai H., Suzuki T., Takahashi Y., Ukai M., Tauchi K., Fujii T., Horikawa N., Minamimura T., Tabuchi Y., Morii M., Tsukada K., Takeguchi N. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett. 2006, 580:3368-3374.
26. Zamuner S.R., Bak A.W., Devchand P.R., Wallace J.L. Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am. J. Pathol. 2005, 167:1293-1300.
27. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122:518-523.
28. Wu W.K., Sung J.J., Yu L., Li Z.J., Chu KM K.M., Cho C.H. Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. Biochem. Biophys. Res. Commun******. 2008, 373:304**-330.
29. Brodie A.M., Lu Q., Long B.J., Fulton A., Chen T., Macpherson N., DeJong P.C., Blankenstein M.A., Nortier J.W., Slee P.H., van de Ven J., van Gorp J.M., Elbers J.R., Schipper M.E., Blijham G.H., Thijssen J.H. Aromatase and COX-2 expression in human breast cancers. J. Steroid Biochem. Mol. Biol. 2001, 79:41-47.
30. Jr Schmedtje J.F., Ji Y.S., Liu W.L., DuBois R.N., Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 1997, 272:601-608.
31. Kim Y., Fischer S.M. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues. J. Biol. Chem. 1998, 273:27686-27694.
32. Miller C., Zhang M., He Y., Zhao J., Pelletier J.P., Martel-Pelletier J., Di Battista J.A. Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: co-stimulation of AP-1 and CRE nuclear binding proteins. J. Cell. Biochem. 1998, 69:392-413.
33. Hernández G.L., Volpert O.V., Iñiguez M.A., Lorenzo E., Martínez-Martínez S., Grau R., Fresno M., Redondo J.M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 2001, 193:607-620.
34. Bonazzi A., Mastyugin V., Mieyal P.A., Dunn M.W., Laniado-Schwartzman M. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J. Biol. Chem. 2000, 275:2837-2844.
35. Bazan N.G., Lukiw W.J. Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells. J. Biol. Chem. 2002, 277:30359-30367.
36. Eisinger A.L., Prescott S.M., Jones D.A., Stafforini D.M. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 2007, 82:147-154.
37. Yeh T.S., Wu C.W., Hsu K.W., Liao W.J., Yang M.C., Li A.F., Wang A.M., Kuo M.L., Chi C.W. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res. 2009, 69:5039-5048.
38. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., Prescott S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 2001, 108:1657-1665.
39. Strillacci A., Griffoni C., Sansone P., Paterini P., Piazzi G., Lazzarini G., Spisni E., Pantaleo M.A., Biasco G., Tomasi V. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp. Cell Res. 2009, 315:1439-1447.
40. Kim S.F., Huri D.A., Snyder S.H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310:1966-1970.
41. Spehlmann M.E., Eckmann L. Nuclear factor-kappa B in intestinal protection and destruction. Curr. Opin. Gastroenterol. 2009, 25:92-99.
42. Deng W.G., Zhu Y., Wu K.K. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 2004, 103:2135-2142.
43. Deng W.G., Zhu Y., Wu K.K. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J. Biol. Chem. 2003, 278:4770-4777.
44. Al-Ashy R., Chakroun I., El-Sabban M.E., Homaidan H.R. The role of NF-kappaB in mediating the anti-inflammatory effects of IL-10 in intestinal epithelial cells. Cytokine 2006, 36:1-8.
45. Ye Y.N., Liu E.S., Shin V.Y., Wu W.K., Cho C.H. The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 2004, 311:123-130.
46. Ye Y.N., Wu W.K., Shin V.Y., Bruce I.C., Wong B.C., Cho C.H. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005, 26:827-834.
47. Sun Y., Chen J., Rigas B. Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis 2009, 30:93-100.
48. Min S.Y., Kim W.U., Cho M.L., Hwang S.Y., Park S.H., Cho C.S., Kim J.M., Kim H.Y. Prostaglandin E2 suppresses nuclear factor-kappaB mediated interleukin 15 production in rheumatoid synoviocytes. J. Rheumatol. 2002, 29:1366-1376.
49. Gomez P.F., Pillinger M.H., Attur M., Marjanovic N., Dave M., Park J., Bingham C.O., Al-Mussawir H., Abramson S.B. Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J. Immunol. 2005, 175:6924-6930.
50. Shishodia S., Koul D., Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J. Immunol. 2004, 173:2011-2022.
51. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., Wolff E., Burt R., Hughes J.P., Warrington J., McPherson J., Wasmuth J., Le Paslier D., Abderrahim H., Cohen D., Leppert M., White R. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66:589-600.
52. Boolbol S.K., Dannenberg A.J., Chadburn A., Martucci C., Guo X.J., Ramonetti J.T., Abreu-Goris M., Newmark H.L., Lipkin M.L., DeCosse J.J., Bertagnolli M.M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996, 56:2556-2560.
53. Hsi L.C., Angerman-Stewart J., Eling T.E. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 1999, 20:2045-2049.
54. Araki Y., Okamura S., Hussain S.P., Nagashima M., He P., Shiseki M., Miura K., Harris C.C. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 2003, 63:728-734.
55. Howe L.R., Subbaramaiah K., Chung W.J., Dannenberg A.J., Brown A.M. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 1999, 59:1572-1577.
56. Haertel-Wiesmann M., Liang Y., Fantl W.J., Williams L.T. Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. J. Biol. Chem. 2000, 275:32046-32051.
57. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
58. Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol. Ther. 2007, 6:832-839.
59. Mukhopadhyay D., Houchen C.W., Kennedy S., Dieckgraefe B.K., Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol. Cell 2003, 11:113-126.
60. Young L.E., Sanduja S., Bemis-Standoli K., Pena E.A., Price R.L., Dixon D.A. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 2009, 136:1669-1679.
61. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
62. Chakrabarty A., Tranguch S., Daikoku T., Jensen K., Furneaux H., Dey S.K. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc. Natl. Acad. Sci. USA 2007, 104:15144-15149.
63. Liu Q., Chan S.T., Mahendran R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 2003, 24:637-642.
64. Takahashi M., Fukuda K., Ohata T., Sugimura T., Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res. 1997, 57:1233-1237.
65. Luceri C., Caderni G., Sanna A., Dolara P. Red wine and black tea polyphenols modulate the expression of cycloxygenase-2, inducible nitric oxide synthase and glutathione-related enzymes in azoxymethane-induced f344 rat colon tumors. J. Nutr. 2002, 132:1376-1379.
66. Kohno H., Suzuki R., Sugie S., Tanaka T. Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci. 2005, 96:69-76.
67. Kojima M., Morisaki T., Tsukahara Y., Uchiyama A., Matsunari Y., Mibu R., Tanaka M. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J. Surg. Oncol. 1999, 70:222-229.
68. Yagihashi N., Kasajima H., Sugai S., Matsumoto K., Ebina Y., Morita T., Murakami T., Yagihashi S. Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch. 2000, 436:109-114.
69. Nosho K., Yoshida M., Yamamoto H., Taniguchi H., Adachi Y., Mikami M., Hinoda Y., Imai K. Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 2005, 26:892-899.
70. Ohta T., Takahashi M., Ochiai A. Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers. Cancer Lett. 2006, 239:246-253.
71. Cianchi F., Cortesini C., Fantappiè O., Messerini L., Sardi I., Lasagna N., Perna F., Fabbroni V., Di Felice A., Perigli G., Mazzanti R., Masini E. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin. Cancer Res. 2004, 10:2694-2704.
72. Moochhala S., Chhatwal V.J., Chan S.T., Ngoi S.S., Chia Y.W., Rauff A. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 1996, 17:1171-1174.
73. Hao X.P., Pretlow T.G., Rao J.S., Pretlow T.P. Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res. 2001, 61:419-422.
74. Bing R.J., Miyataka M., Rich K.A., Hanson N., Wang X., Slosser H.D., Shi S.R. Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin. Cancer Res. 2001, 7:3385-3392.
75. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
76. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Ushikubi F., Narumiya S., Sugimura T., Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999, 59:5093-5096.
77. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., Wakabayashi K. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002, 62:28-32.
78. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Oshima M., Taketo M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 2001, 7:1048-1051.
79. Seno H., Oshima M., Ishikawa T.O., Oshima H., Takaku K., Chiba T., Narumiya S., Taketo M.M. Ooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002, 62:506-511.
80. Amano H., Hayashi I., Endo H., Kitasato H., Yamashina S., Maruyama T., Kobayashi M., Satoh K., Narita M., Sugimoto Y., Murata T., Yoshimura H., Narumiya S., Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 2003, 197:221-232.
81. Han C., Michalopoulos G.K., Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell. Physiol. 2006, 207:261-270.
82. Donnini S., Finetti F., Solito R., Terzuoli E., Sacchetti A., Morbidelli L., Patrignani P., Ziche M. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J. 2007, 21:2418-2430.
83. Mendez M., LaPointe M.C. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H2111-H2117.
84. Itakura Y., Sasano H., Shiga C., Furukawa Y., Shiga K., Mori S., Nagura H. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994, 74:795-804.
85. Filipe M.I., Osborn M., Linehan J., Sanidas E., Brito M.J., Jankowski J. Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. Br. J. Cancer 1995, 71:30-36.
86. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
87. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
88. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
89. Kauffmann-Zeh A., Thomas G.M., Ball A., Prosser S., Cunningham E., Cockcroft S., Hsuan J.J. Requirement for phosphatidylinositol transfer protein in epidermal growth factor signaling. Science 1995, 268:1188-1190.
90. Park O.K., Schaefer T.S., Nathans D. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 1996, 16:1595-1603.
91. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 2002, 8:289-293.
92. Pai R., Nakamura T., Moon W.S., Tarnawski A.S. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J. 2003, 17:1640-1647.
93. Buchanan F.G., Wang D., Bargiacchi F., DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 2003, 278:35451-35457.
94. Tessner T.G., Muhale F., Riehl T.E., Anant S., Stenson W.F. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J. Clin. Invest. 2004, 114:1676-1685.
95. Shao J., Lee S.B., Guo H., Evers B.M., Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res. 2003, 63:5218-5223.
96. Yu L., Wu W.K., Li Z.J., Wong H.P., Tai E.K., Li H.T., Wu Y.C., Cho C.H. E series of prostaglandin receptor 2-mediated activation of extracellular signal-regulated kinase/activator protein-1 signaling is required for the mitogenic action of prostaglandin E2 in esophageal squamous-cell carcinoma. J. Pharmacol. Exp. Ther. 2008, 327:258-267.
97. Yu L., Wu W.K., Li Z.J., Li H.T., Wu Y.C., Cho C.H. Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. Int. J. Cancer 2009, 125:2540-2546.
98. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schrör K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999, 59:198-204.
99. Kolch W., Heidecker G., Kochs G., Hummel R., Vahidi H., Mischak H., Finkenzeller G., Marmé D., Rapp U.R. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993, 364:249-252.
100. Schönwasser D.C., Marais R.M., Marshall C.J., Parker P.J. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol. 1998, 18:790-798.
101. Krysan K., Reckamp K.L., Dalwadi H., Sharma S., Rozengurt E., Dohadwala M., Dubinett S.M. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005, 65:6275-6281.
102. Dajani O.F., Meisdalen K., Guren T.K., Aasrum M., Tveteraas I.H., Lilleby P., Thoresen G.H., Sandnes D., Christoffersen T. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. J. Cell. Physiol. 2008, 214:371-380.
103. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 2002, 4:E131-E136.
104. Segditsas S., Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006, 25:7531-7537.
105. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510.
106. Lim K., Han C., Xu L., Isse K., Demetris A.J., Wu T. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 2008, 68:553-560.
107. Hernández-Díaz S., García-Rodríguez L.A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am. J. Med. 2001, 110(4):20S-27S.
108. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
109. Helin-Salmivaara A., Virtanen A., Vesalainen R., Grönroos J.M., Klaukka T., Idänpään-Heikkilä J.E., Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur. Heart J. 2006, 27:1657-1663.
110. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006, 116:4-15.
111. Makita H., Mutoh M., Maruyama T., Yonemoto K., Kobayashi A., Fujitsuka H., Toida M., Shibata T., Miyamoto S., Yasui Y., Suzuki R., Wakabayashi K., Tanaka T. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Carcinogenesis 2007, 28:677-684.
112. Kaneshiro T., Okumura M., Maalouf S., Uflacker A., Maruyama T., Kawamori T. Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins Other Lipid Mediat. 2009, 90:31-36.